Our team has an innovative technology platform that is well positioned to disrupt the current genetic diagnostics market by combining the strength of targeted sequence enrichment, third-generation sequencing, and machine learning. Our state-of-the-art proprietary targeted sequencing technology improves detection sensitivity and reduces cost. Unlike the commercial NGS targeted sequencing solutions, our technology has no bias in gene coverage and no compromise on DNA length or data throughput. Our technology works with routine clinical samples (e.g. a simple blood draw) and provides ultra-long native DNA reads (>1000X NGS read length) that can resolve any type of genetic variants. The technology is highly amenable to multiplexing and is customizable to any gene panels (e.g. genetic disease or cancer gene panels). Our targeted sequencing workflow can run on the pocket-sized Nanopore MinION sequencer connected to a laptop. Sequencing data can be analyzed in real time by a set of novel analysis tools based on machine learning algorithms and generate the genetic variants information on the spot. With the help of a portable hands-free automatic sample preparation device called VolTRAX, the entire sequencing setup can be brought in a briefcase to remote locations and run by any clinical technician without special training in NGS. For the first time, our technologies enable the accurate and cost-effective sequencing of relevant genes and genomes in real-time anywhere on earth.
Precision medicine is the most promising frontier of modern medicine that leverages biomedical big data and advanced analytics, such as artificial intelligence, to deliver accurate and effective healthcare to society on a personalized basis.